Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

43.86
+6.9118.70%
Volume:7.90M
Turnover:345.31M
Market Cap:12.09B
PE:24.92
High:45.29
Open:40.52
Low:40.47
Close:36.95
Loading ...

Exelixis Price Target Maintained With a $40.00/Share by RBC Capital

Dow Jones
·
56 mins ago

Why Exelixis Stock Is Skyrocketing Today

Motley Fool
·
Yesterday

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

Benzinga
·
Yesterday

Exelixis Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Yesterday

These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, Oklo, American Eagle, Exelixis, Grail, and More -- Barrons.com

Dow Jones
·
Yesterday

Stock Track | Exelixis Soars 9.66% on Strong Q1 Results and Raised 2025 Outlook

Stock Track
·
Yesterday

BUZZ-Exelixis rises after lifting 2025 revenue forecast

Reuters
·
Yesterday

Exelixis Shares up 4.4% Premarket After Q1 Revenue Beat

THOMSON REUTERS
·
Yesterday

Exelixis price target raised to $47 from $40 at Morgan Stanley

TIPRANKS
·
Yesterday

Exelixis Inc : Stifel Raises Target Price to $38 From $36

THOMSON REUTERS
·
Yesterday

Morgan Stanley Adjusts Price Target on Exelixis to $47 From $40, Maintains Overweight Rating

MT Newswires Live
·
Yesterday

Stock Track | Exelixis Soars 7.01% Pre-market on Strong Q1 Results and Raised 2025 Outlook

Stock Track
·
Yesterday

U.S. Stocks to Watch: Nvidia, AMD, UnitedHealth, American Eagle, Exelixis, Grail, and More

Dow Jones
·
Yesterday

U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth

Reuters
·
Yesterday

Stock Track | Exelixis Soars 6.36% After Hours on Strong Q1 Results and Raised 2025 Outlook

Stock Track
·
Yesterday

Stock Track | Exelixis Shares Soar 6.36% on Strong Q1 Results and Raised 2025 Guidance

Stock Track
·
Yesterday

Exelixis’s Strong Financial Performance and Promising Pipeline Drive Optimistic Outlook and Increased Price Target

TIPRANKS
·
Yesterday

Closing Bell Movers: Exelixis up 6% on earnings beat

TIPRANKS
·
Yesterday

Exelixis initiated dose-escalation stage of first human Phase 1 study of XB628

TIPRANKS
·
Yesterday

Exelixis Inc. Initiates Phase 1 Clinical Trial for First-in-Class Bispecific Antibody XB628 in Advanced Solid Tumors

Reuters
·
Yesterday